- $1.1 BnWorld market, 2023
- $2.2 BnProjected, 2033
- 7.4%Growth a year (CAGR)
- 1,228Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$462 Mn
5.4% a year · 42% of the world -
2
China
$88 Mn
8.9% a year · 8% of the world -
3
Canada
$88 Mn
7.4% a year · 8% of the world -
4
Japan
$68 Mn
7.9% a year · 6.2% of the world -
5
Germany
$40 Mn
5.6% a year · 3.7% of the world -
6
France
$30 Mn
6.4% a year · 2.8% of the world -
7
UK
$29 Mn
5.4% a year · 2.6% of the world -
8
Brazil
$28 Mn
8.4% a year · 2.5% of the world -
9
Italy
$26 Mn
6.9% a year · 2.4% of the world -
10
Ecuador
$22 Mn
8% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
Spain
AustraliaBone Cancer Diagnostic by country and region
India
Saudi Arabia
Mexico
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 6,180 papers since 2021
- Superficial Ewing Sarcoma and Neurocristic FET::ETS Tumors: Defining a Diagnostic Gray Zone. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2026
- Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin-Resistant Osteosarcoma Organoids. MedComm, 2026
- Malignant Giant Cell Tumor of Bone: A Clinicopathological Analysis of 15 Cases. Human mutation, 2026
- Epigenetic patterns and methylation-based models for robust outcome prediction in osteosarcoma. medRxiv : the preprint server for health sciences, 2026
- Unusual Morphologic Variants of Solitary Fibrous Tumor: A Case Series of 17 Cases Featuring 10 Distinct Histomorphologies. Human pathology, 2026
Compare Bone Cancer Diagnostic side by side
Key companies in Bone Cancer Diagnostic
GE Healthcare
Roche Diagnostics
Becton, Dickinson and Company (BD)
Philips Healthcare
Siemens Healthineers
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Amgen Inc.
Quick answers
How big is the Bone Cancer Diagnostic market?
The world Bone Cancer Diagnostic market was worth about $1.1 Bn in 2023 and is projected to reach $2.2 Bn by 2033, growing 7.4% a year (CAGR).
Which country has the largest Bone Cancer Diagnostic market?
The US is the largest of the 24 countries we cover, at $462 Mn in 2023. India grows fastest, at 10.4% a year.
How many clinical trials are running in Bone Cancer Diagnostic?
ClinicalTrials.gov lists 1,228 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Bone Cancer Diagnostic?
PubMed lists about 6,180 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.